Back to Trials
NCT05899439RecruitingAccepts Healthy Volunteers

Immune Function and the Progression to T1D

University of Florida

Start Date

1/1/2005

Completion Date

1/1/2085

Summary

To elucidate the mechanisms by which type 1 diabetes-associated genes; IFIH1, TYK2, IKZF4, as well as total genetic risk, impart functional immunoregulatory abnormalities that result in expansion of self-reactive adaptive immune cells, defective regulatory/effector mechanisms in T cells, inflammatory antigen presenting cells, and abnormal immune function in T cells and B cells.

Detailed Description

Newly proposed studies will identify the inflammatory cues that draw immune cells into islets for disease initiation (Project 1); probe the motility of immune cells through inflamed vasculature to the target organ and antigen priming sites within secondary lymphatics (Project 2); and characterize the T1D-associated adaptive immune signatures in blood and immune tissues (Project 3). The overall hypothesis of the renewed P01 states: 1) the impact of T1D-risk variants will vary by tissue, cell subset, and activation state, and 2) risk variants, cellular stress, and defects in immunologic pathways are key to engender the autoimmune destruction of pancreatic B-cells that results in T1D.

Eligibility Criteria

Age Range: No minimum to 100 years

Inclusion Criteria: able to have blood drawn - Exclusion Criteria: none \-

Interventions

OTHER

blood draw

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Type 1 Diabetes

Locations

Kieran McGrail

Gainesville, Florida 32610

United States

The Ohio State University

Columbus, Ohio 43210

United States

Baylor College of Medicine, Center for Research Advancement - Texas Children's Hospital

Houston, Texas 77030

United States